Evidence map›Paper›PMID 33099562›Full record

ArticleKorean journal of ophthalmology : KJO2020

Serum Cystatin C Concentrations in Patients with Graves' Ophthalmopathy.

Nagehan Can, Ercan Ozsoy, Sabiha Gungor Kobat, Elif Yusufoglu, Nevin Ilhan, Tamer Demir

Open access · goldAbstract read
In one paragraph

Article in Korean journal of ophthalmology : KJO, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 1 country.

Nagehan CanDepartment of Ophthalmology, Torbali State Hospital, Izmir, Turkey.
Ercan OzsoyDepartment of Ophthalmology, Haseki Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Sabiha Gungor KobatDepartment of Ophthalmology, Elazıg Training and Research Hospital, University of Health Sciences, Elazıg, Turkey.
Elif YusufogluDepartment of Ophthalmology, Elazıg Training and Research Hospital, University of Health Sciences, Elazıg, Turkey.
Nevin IlhanDepartment of Biochemistry, Firat University School of Medicine, Elazıg, Turkey.
Tamer DemirDepartment of Ophthalmology, Canakkale Onsekiz Mart University School of Medicine, Canakkale, Turkey.
Çanakkale Onsekiz Mart Üniversitesi · TRElazığ Eğitim ve Araştırma Hastanesi · TRFırat University · TRHaseki Eğitim ve Araştırma Hastanesi · TRSağlık Bilimleri Üniversitesi · TRSivas State Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the concentration of serum cystatin C (CysC) in patients with Graves' ophthalmopathy (GO) and the usability of the serum CysC concentrations in the follow-up of the disease.

methodsThirty patients with GO and 30 healthy age-matched volunteers were included in this cross-sectional study. GO was diagnosed based on the European Group on Graves' Orbitopathy consensus. Serum thyroid-stimulating hormone, free triiodothyronine, free thyroxine, and CysC concentrations were measured in the participants. The serum CysC concentrations were compared between patients with GO and controls. Patients with GO were subdivided into hyperthyroid and euthyroid patients, and their serum CysC concentrations were compared. In addition, the CysC concentrations in hyperthyroid and euthyroid patients with GO were compared separately with those of healthy subjects. Kruskal-Wallis test and Student's t-test were used for statistical evaluation.

resultsThe mean serum CysC concentrations in GO patients and controls were 1.04 ± 0.36 and 0.74 ± 0.09 mg/L, respectively. There was a statistically significant difference in the serum CysC concentrations between patients with GO and control subjects (p < 0.001). Fifteen patients had hyperthyroid status, and 15 patients had euthyroid status. The mean serum CysC concentrations in hyperthyroid and euthyroid patients with GO were 1.35 ± 0.22 and 0.72 ± 0.13 mg/L, respectively. Serum CysC concentrations were significantly higher in hyperthyroid patients than in euthyroid patients (p = 0.001). In addition, hyperthyroid patients had significantly higher serum CysC concentrations than healthy subjects. Among patients with GO, 21 and nine had mild and moderate-to-severe GO, respectively. Active and inactive GO were observed in eight and 22 patients, respectively.

conclusionsThe serum CysC concentrations in hyperthyroid patients were higher than those in healthy subjects. Moreover, hyperthyroid patients had higher serum CysC concentrations than euthyroid patients. Further studies with a larger sample size are needed to confirm these results.

Indexed as

AdultBiomarkersCross-Sectional StudiesCystatin CFemaleGraves OphthalmopathyHumansMaleBiomarkersCystatin CCystatin CExophthalmosSerumThyroxineTriiodothyronine

Identifiers

PMID33099562
PMCPMC7597615
OpenAlexW3093508050

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.